

1 Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality
2 in residents of Long-Term Care Facilities in the VIVALDI study

3

4 Oliver Stirrup¹, Madhumita Shrotri², Natalie L. Adams², Maria Krutikov², Borscha Azmi², Igor Monakhov³,
5 Gokhan Tut⁴, Paul Moss⁴, Andrew Hayward^{5,6}, Andrew Copas¹, Laura Shallcross²

6

7 ¹ Institute for Global Health, University College London, London, UK

8 ² UCL Institute of Health Informatics, London, UK

9 ³ UK Health Security Agency, London, UK

10 ⁴ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

11 ⁵ UCL Institute of Epidemiology & Healthcare, London, UK

12 ⁶ Health Data Research UK, London, UK

13

14 Correspondence to: Dr Oliver Stirrup, UCL Institute for Global Health, 222 Euston Road, London NW1 2DA,

15 UK. oliver.stirrup@ucl.ac.uk

16 Alternate corresponding author: Laura Shallcross, UCL Institute of Health Informatics, 222 Euston Road,

17 London NW1 2DA, UK. l.shallcross@ucl.ac.uk

18

19 **Keywords:** SARS-CoV-2; COVID-19; Omicron; Vaccine effectiveness; long-term care facilities.

20 **Running title:** Booster vaccines in older care residents

21 **Author contributions:** OS conducted statistical analyses and drafted Methods and Results, with MS and AC
22 contributing to coding of data processing and analysis. NLA contributed to Introduction and Discussion. MK,
23 BA, GT, PM, AH, AC and LS are involved in the planning, recruitment and organisation of the Vivaldi cohort
24 study. IM worked on data processing and linkage. GT and PM conduct lab work for the study. LS, AC, AH
25 obtained funding for the study. All authors contributed to the planning and interpretation of this analysis, and
26 contributed to the final manuscript draft.

27 **Abstract**

28 We evaluated the effectiveness of 1-3 booster vaccinations against SARS-CoV-2 related mortality
29 among a cohort of 13407 older residents of long-term care facilities (LTCFs) participating in the
30 VIVALDI study in England in 2022. Cox regression was used to estimate relative hazards of SARS-
31 CoV-2 related death following booster vaccination relative to 2 doses (after 84+ days), stratified by
32 previous SARS-CoV-2 infection and adjusting for age, sex and LTCF capacity. Each booster
33 provided additional short-term protection relative to primary vaccination, with consistent pattern of
34 waning to 45-75% reduction in risk beyond 112 days.

35

36 Introduction

37 Long-term care facilities (LTCFs) in the UK were severely impacted by COVID-19 early in the
38 pandemic[1]. As such, LTCF staff and residents were prioritised for primary vaccination against
39 SARS-CoV-2 starting in December 2020[2] and for additional rounds of booster vaccination from
40 September 2021, March 2022 and September 2022.

41 We previously reported waning of protection against infection and severe clinical outcomes following
42 primary course vaccination in LTCF residents from 84 days (12 weeks) following second dose [3],
43 with an improvement in protection against severe outcomes observed following first booster vaccine
44 dose (third dose)[3] that remained after emergence of the Omicron variant[4]. This study aims to
45 produce an updated evaluation of the effectiveness of third, fourth and fifth dose booster vaccination
46 against SARS-CoV-2 associated death amongst residents of LTCFs in England over the year 2022.

47 We focused on the outcome of mortality because of changes to testing policy in LTCFs in the UK
48 within the period analysed, which make it challenging to analyse effects on SARS-CoV-2 infection
49 incidence or to evaluate hospital admissions in a timely manner.

50 Methods

51 VIVALDI is a prospective cohort study investigating SARS-CoV-2 in LTCF residents and staff in
52 England [5]. For this study, the analysis period is defined from January 1 2022 to 31 December 2022,
53 and residents aged >65 years were eligible for inclusion if they had at least one polymerase chain
54 reaction (PCR) or lateral flow device (LFD) result linked to a participating LTCF available within this
55 period. Following national guidelines, residents underwent monthly routine PCR testing until the end
56 of March 2022, when the policy switched to symptomatic and outbreak testing only. The analysis
57 period was chosen to allow our prior estimates of vaccine effectiveness to be updated whilst retaining
58 a period when asymptomatic testing was still in use, allowing identification of the cohort of residents
59 in participating LTCFs in early 2022. As previously, we excluded individuals who had not received at

60 least two vaccine doses before the analysis period[4] because unvaccinated residents are substantially
61 more likely to be receiving end of life care.

62 As previously we retrieved all available PCR and LFD results from the national testing programme
63 through the COVID-19 Datastore. Test results and vaccination (National Immunisation Management
64 Service) and mortality (Office for National Statistics) data from national records were linked to study
65 participants using pseudo-identifiers based on National Health Service (NHS) numbers[3]. COVID-19
66 death was defined as death within 28 days of positive PCR or LFD test or with COVID-19 recorded
67 as primary or secondary cause of death on the death certificate. SARS-CoV2 serological test results
68 for IgG antibodies to the nucleocapsid protein (Abbott ARCHITECT system (Abbott, Maidenhead,
69 UK)) were linked in a subset of participants who consented to blood sampling specifically for the
70 VIVALDI study[6].

71

72 **Statistical analysis**

73 We examined individual-level vaccine effectiveness against SARS-CoV-2 associated death.
74 Individuals were eligible for inclusion if they had complete data on sex and age, had received at least
75 2 vaccine-doses 84 days before analysis start date, had at least one PCR or LFD test result recorded
76 within the analysis period and were linked to a LTCF participating in VIVALDI with data on total
77 number of staff and residents. Individuals with third vaccine dose recorded before September 14
78 2021, fourth dose before March 21 2022 and fifth dose before September 5 2022 were excluded as
79 these dates corresponded to national roll-out to residents of these doses.

80

81 We used Cox regression models to derive adjusted hazard ratios (HRs) for risk of SARS-CoV-2
82 linked death. Vaccination status was included as a time-varying covariable. The reference category
83 was 2 vaccine doses, with ≥ 84 days elapsed from Dose 2 (although this was varied to create graphical
84 summaries of the estimated effect of successive doses). Exposure categories were 0–13, 14–48, 49–
85 83, 84–111, 112–139 and ≥ 140 days following Dose 3 and Dose 4, and 0–13, 14–48, 49–83 and ≥ 84
86 days following Dose 5. Individuals entered the risk period on 1 January 2022, or date of their first

87 recorded PCR/LFD result within VIVALDI if later. Individuals with positive PCR/LFD result within
88 30 days prior to 1 January 2022 entered the risk period from the 31st day post-positive test.
89 Individuals exited the risk period at the earliest of: death or end of analysis period. Individuals were
90 additionally censored at 29 days post-positive SARS-CoV-2 test if they survived to this point;
91 COVID-related death from the original infection would be possible beyond this time but the
92 individual would also be at lower risk for a new SARS-CoV-2 infection, and so censoring at 29 days
93 was chosen to match our mortality outcome definition. Baseline hazard was defined over calendar
94 time. 95% CIs were calculated using robust SEs accounting for dependence of infection events within
95 LTCFs. Analysis was stratified by evidence of SARS-CoV2 infection prior to the risk period. We
96 adjusted for sex (binary variable), age (5-knot restricted cubic spline term) and LTCF size expressed
97 as total number of beds (linear term). All statistical analyses were conducted using STATA 17.0.

98

99 **Patient Consent Statement**

100 Patient consent was not obtained for data use other than for those patients who underwent blood
101 sampling specifically for the VIVALDI study. The legal basis to access data from residents without
102 informed consent is provided by Health Research Authority Confidentiality Advisory Group approval
103 (21/CAG/0156). Ethical approval was obtained from South Central-Hampshire B Research Ethics
104 Committee (20/SC/0238).

105

106 **Results**

107 13407 residents from 327 LTCFs were included, following exclusion of 1051 because 2-dose
108 vaccination had not been completed more than 84 days before start of the analysis period, 194
109 because booster vaccination doses were recorded prior to national roll-out and 904 for whom a
110 positive SARS-CoV-2 test was recorded on the first day of their at-risk period. 3411 residents
111 (25.4%) had recorded evidence of SARS-CoV-2 infection prior to the analysis period. The median

112 age was 86.6 years (IQR, 80.2-91.8). 4132 residents died during the analysis period, of which 428
113 were associated with SARS-CoV-2.

114 12072 (90.0%) residents had received third-dose booster vaccination dose prior to the analysis period,
115 and 13104 (97.7%) by the end (98.8% of those surviving to year-end) (Figure 1). First booster doses
116 were Pfizer in the majority (n=12474, 95.2%), with Moderna also used (n=593, 4.5%). Second
117 boosters (fourth dose) had been received by 10846 (80.9%, 93.0% of survivors) and third boosters
118 (fifth dose) by 7311 (54.5%, 70.8% of survivors) of residents by end of analysis period. The majority
119 were Moderna vaccines for second booster (6421 (59.2%)) and for third booster (5991 (81.9%)).
120 8621 (64.3%) residents had received a bivalent vaccine by end of study period, mostly as third booster
121 dose but in some as first (n=120) or second (n=1455) booster received.

122

123 In residents without known prior SARS-CoV-2 infection, first booster reduced risk of SARS-CoV-2
124 linked death after 0-13 days (none observed), 14-48 days (HR 0.20, 0.07-0.58), 49-83 days (0.25,
125 0.13-0.47) and 84-111 days (0.30, 0.18-0.51), with some apparent waning in level of protection by
126 112-139 days (0.44, 0.28-0.69) and 140+ days (0.38, 0.24-0.61) (Figure 2, Table 1). A similar pattern
127 was observed following fourth and fifth dose vaccination, although confidence intervals for HRs were
128 wider for fourth dose beyond 84 days and for fifth dose (Figure 2d) because of lower available
129 follow-up time and lower incidence of SARS-CoV-2 infection in the latter half of 2022. Residents
130 with known infection prior to the analysis period were at reduced risk of death relative to those
131 without prior infection (0.55, 0.28-1.08; among those with 2-dose vaccination). Within this group, the
132 pattern of further protection from booster vaccination was similar to those without known prior
133 infection, although there is greater uncertainty in estimates. Adding a parameter to the model
134 representing receipt of a bivalent (BA.1) vaccine indicated possible greater protection but with a wide
135 confidence interval (0.81, 0.29-2.25).

136

137 Discussion

138 We found evidence that third, fourth and fifth dose booster vaccination provide additional short-term
139 protection against SARS-CoV-2 linked mortality among LTCF residents, relative to primary
140 vaccination only. This is consistent with data on fourth dose vaccination of LTCF residents in the
141 USA[7] and Canada[8]. The pattern of waning of protection appeared to be similar for successive
142 booster doses, stabilising at a 45-75% reduction in risk beyond 112 days (16 weeks).

143 Our data suggest that the combination of booster vaccination with prior SARS-CoV-2 infection
144 provides particularly strong protection against subsequent mortality from the virus, in line with
145 previous studies in the general population[9]. We are likely to have underestimated the protective
146 effect of prior infection in this analysis, as we have previously found the cumulative incidence of
147 detected SARS-CoV-2 infection to be substantially higher among residents who have undergone
148 testing for anti-nucleocapsid antibodies[6]. This suggests that many of the ‘unexposed’ group in our
149 analyses may have in fact been infected prior to the risk period, although the prevalence of prior
150 infection may be lower in residents who were admitted to care homes in the second half of 2021 and
151 2022 compared to those resident since 2020.

152 It is possible that the primarily bivalent fifth dose vaccination provided some additional long-term
153 protection, but the pattern of reduction in risk over time did not differ markedly from that observed
154 for prior booster doses. This is consistent with data from the general population in the USA[10],
155 perhaps due to the fact that different Omicron sub-lineages were circulating by the time that bivalent
156 vaccines based on the BA.1 lineage were rolled out[11].

157 Funding

159 This work is independent research funded by the Department of Health and Social Care (COVID-19
160 surveillance studies). MK is funded by a Wellcome Trust Clinical PhD Fellowship (222907/Z/21/Z). LS is

161 funded by a National Institute for Health Research Clinician Scientist Award (CS-2016-007). AH is supported
162 by Health Data Research UK (LOND1), which is funded by the UK Medical Research Council, Engineering and
163 Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social
164 Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health
165 and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern
166 Ireland), British Heart Foundation, and Wellcome Trust.

167 Potential Conflicts of Interest

168 LS reports grants from the Department of Health and Social Care during the conduct of the study and is a
169 member of the Social Care Working Group, which reports to the Scientific Advisory Group for Emergencies.
170 AH reports funding from the COVID Core Studies Programme and is a member of the New and Emerging
171 Respiratory Virus Threats Advisory Group at the Department of Health and Environmental Modelling Group of
172 the Scientific Advisory Group for Emergencies. All other authors declare no competing interests.

173

174 Acknowledgements

175 We thank the staff and residents in the long-term care facilities who participated in this study and Mark
176 Marshall at National Health Service (NHS) England who pseudonymised the electronic health records. The
177 views expressed in this publication are those of the authors and not necessarily those of the NHS or the UK
178 Health Security Agency.

179

180 References

- 181 1. Chudasama DY, Milbourn H, Nsonwu O, et al. Penetration and impact of COVID-19
182 in long term care facilities in England: population surveillance study. *Int J Epidemiol*
183 **2022**; 50(6): 1804-13.
- 184 2. Department of Health and Social Care. Independent report. Priority groups for
185 coronavirus (COVID-19) vaccination: advice from the JCVI, 30 December 2020.
186 Available at: [https://www.gov.uk/government/publications/priority-groups-for-](https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020)
187 [coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020](https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020). Accessed
188 14 April 2022.

- 189 3. Shrotri M, Krutikov M, Nacer-Laidi H, et al. Duration of vaccine effectiveness
190 against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of
191 long-term care facilities in England (VIVALDI): a prospective cohort study. *The*
192 *Lancet Healthy Longevity* **2022**; 3(7): e470-e80.
- 193 4. Stirrup O, Shrotri M, Adams NL, et al. Clinical Effectiveness of SARS-CoV-2
194 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care
195 Facilities: A Prospective Cohort Study (VIVALDI). *Open Forum Infectious Diseases*
196 **2022**; 10(1).
- 197 5. Krutikov M, Palmer T, Donaldson A, et al. Study Protocol: Understanding SARS-
198 Cov-2 infection, immunity and its duration in care home residents and staff in
199 England (VIVALDI). *Wellcome Open Res* **2020**; 5: 232.
- 200 6. Krutikov M, Palmer T, Tut G, et al. Prevalence and duration of detectable SARS-
201 CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over
202 the first year of the pandemic (VIVALDI study): prospective cohort study in England.
203 *The Lancet Healthy Longevity* **2022**; 3(1): e13-e21.
- 204 7. McConeghy KW. Effectiveness of a second COVID-19 vaccine booster dose against
205 infection, hospitalization, or death among nursing home residents—19 States, March
206 29–July 25, 2022. *MMWR Morbidity and Mortality Weekly Report* **2022**; 71.
- 207 8. Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19
208 mRNA vaccine against the omicron variant among long term care residents in
209 Ontario, Canada: test negative design study. *BMJ* **2022**; 378: e071502.
- 210 9. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2
211 infection and hybrid immunity against the omicron variant and severe disease: a
212 systematic review and meta-regression. *The Lancet Infectious Diseases* **2023**.
- 213 10. Link-Gelles R. Effectiveness of bivalent mRNA vaccines in preventing symptomatic
214 SARS-CoV-2 infection—increasing community access to testing program, United
215 States, September–November 2022. *MMWR Morbidity and Mortality Weekly Report*
216 **2022**; 71.
- 217 11. Offit PA. Bivalent Covid-19 Vaccines — A Cautionary Tale. *New England Journal of*
218 *Medicine* **2023**; 388(6): 481-3.
- 219

220 Figures

221 **Figure 1** Plot of booster vaccination status of residents of long term care facilities included in the
222 analysis. The percentage of residents with each number of vaccine doses is given among those in
223 follow-up for the analysis at any given point in time.

224 **Figure 2** Plot of estimated hazard ratio (HR) for SARS-CoV-2 linked death (within 28 days of a
225 positive PCR or LFD test, and/or recorded on death certificate) following receipt of booster vaccine
226 doses, among long term care facility residents without evidence of prior SARS-CoV-2 infection (a-c)
227 and in those with prior SARS-CoV-2 infection (d). Results are shown for 3-5 doses relative to 2-dose
228 vaccination in (a) and (d), for 4 doses relative to 3 doses beyond 140 days in (b) and for 5 doses
229 relative to 4 doses beyond 140 days in (c).

230

231

232

233 Tables

234 **Table 1** Crude event rates and adjusted hazard ratios against SARS-CoV-2 associated death
 235 (within 28 days of a positive PCR or LFD test, and/or recorded on death certificate) for LTCF
 236 residents, by prior SARS-CoV-2 exposure, and vaccination status

SARS-CoV-2 mortality						
Prior SARS-CoV-2 exposure	Vaccination status	Person-days	Deaths	IR /1000pd	HR (95% CI)*	HR (95% CI) *
Unexposed	D2 84+d	71837	35	0.49	Ref.	
	D3 0-13d	6471	0	0	0.00 (0.00-0.00)	
	D3 14-48d	39206	4	0.1	0.20 (0.07-0.58)	
	D3 49-83d	115192	15	0.13	0.25 (0.13-0.47)	
	D3 84-111d	193274	39	0.2	0.30 (0.18-0.51)	
	D3 112-139d	189472	50	0.26	0.44 (0.28-0.69)	
	D3 140+d	432958	81	0.19	0.38 (0.24-0.61)	
	D4 0-13d	66886	2	0.03	0.06 (0.01-0.25)	
	D4 14-48d	176815	10	0.06	0.16 (0.07-0.33)	
	D4 49-83d	168385	15	0.09	0.24 (0.11-0.54)	
	D4 84-111d	119450	14	0.12	0.28 (0.12-0.63)	
	D4 112-139d	92701	16	0.17	0.57 (0.27-1.20)	
	D4 140+d	90740	11	0.12	0.32 (0.15-0.68)	
	D5 0-13d	43722	1	0.02	0.05 (0.01-0.35)	
	D5 14-48d	114653	8	0.07	0.12 (0.05-0.29)	
	D5 49-83d	99414	10	0.1	0.26 (0.11-0.66)	
D5 84+d	41549	5	0.12	0.25 (0.08-0.77)		
Exposed	D2 84+d	40015	11	0.27	0.55 (0.28-1.08)	Ref.
	D3 0-13d	3932	0	0		—
	D3 14-48d	20433	0	0		—
	D3 49-83d	51452	4	0.08		0.27 (0.09-0.86)
	D3 84-111d	81134	13	0.16		0.45 (0.20-0.98)
	D3 112-139d	78516	8	0.1		0.31 (0.12-0.85)
	D3 140+d	174497	12	0.07		0.26 (0.11-0.59)
	D4 0-13d	29654	0	0		—
	D4 14-48d	78026	2	0.03		0.13 (0.03-0.58)
	D4 49-83d	74409	1	0.01		0.07 (0.01-0.54)
	D4 84-111d	52959	3	0.06		0.24 (0.06-0.98)
	D4 112-139d	40544	2	0.05		0.30 (0.06-1.43)
	D4 140+d	38498	6	0.16		0.81 (0.28-2.33)
	D5 0-13d	19276	0	0		—
	D5 14-48d	49902	2	0.04		0.12 (0.03-0.60)
	D5 49-83d	43712	4	0.09		0.45 (0.12-1.65)
D5 84+d	19395	4	0.21		0.79 (0.20-3.07)	

237 *HR values in the two columns are from mathematically identical statistical models, but HRs in right-hand

238 column are expressed relative to ‘D2 84+d’ vaccine status in individuals with prior SARS-CoV-2 infection.



